在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Using genetic tools, the scientists then blocked TYK2 in the mice with Alzheimer's. This resulted in a reduction in the ...

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $9.82, but opened at ...

But this study found that the enzyme tyrosine kinase 2 (TYK2), which plays a central role in the immune system ... The finding that lowering or blocking TYK2 could treat Alzheimer's is encouraging, as ...